



Transmucosis appoints Dr. Maria Nichol to lead Corporate Development and IP

- ***Dr. Maria Nichol brings over two decades of transactional and IP experience in life sciences***
- ***Further strengthening of the leadership team on the road to the clinic***

College Park MD, USA, 31 July 2025 – Transmucosis LLC (“Transmucosis” or the “Company”), a private biotechnology company pioneering a novel intranasal vaccine platform, today announces the appointment of Dr. Maria Nichol EPA, CPA as Head of Corporate Development Intellectual Property.

Dr. Maria Nichol (DPhil, Oxford University, UK) was Vice President of Corporate Development and IP at Galapagos NV for 16 years (2006-2022). During this time she was responsible for the filing, prosecution and maintenance of >70 patent families. Furthermore, she formed part of the transactions team that executed multiple strategic pharma partnerships. Since leaving Galapagos she has been working with biotechnology companies in EU and US to support their IP and BD strategy.

Herbert Heyneker, CEO of Transmucosis, said: “We are very proud that Maria has joined our team. We are ambitious to advance our development candidates to clinical development. Maria’s experience in IP and transactions will be invaluable as we develop Transmucosis to become a biotech company with a clinical pipeline.”

-ENDS-

For more information, please contact:

Transmucosis LLC

Herbert Heyneker, CEO

hheyneker@transmucosis.com

About Transmucosis

Transmucosis is a developer of protein-based intranasal vaccines against respiratory diseases. It leverages the unique properties of the FcRn receptor to facilitate the passage of nasal vaccines across the mucosal surface. Transmucosis developed multiple influenza vaccines. Furthermore, the company obtained preclinical proof of concept with intranasal vaccines against all tested strains of coronavirus, and against RSV. Transmucosis LLC was founded by Dr. Herbert Heyneker (CEO) and Prof. Dr. Xiaoping Zhu (CSO). Transmucosis signed an exclusive license agreement with the University of Maryland covering all research on the intranasal vaccine platform by the lab of Prof. Zhu’s. The lab has been funded for more than a decade by NIH and other grants. The company is located at 8075 Greenmead Drive, College Park, Maryland 20742-3711, USA.